As Biogen stock soared 38% Monday on the surprise Food and Drug Administration approval of its hotly debated treatment for Alzheimer’s disease, investors bid up the shares of would-be competitors large and small.

Eli Lilly was the biggest beneficiary, rising nearly 12% and adding more than $20 billion in market capitalization. Like Biogen’s drug, called Aduhelm, Lilly’s most advanced Alzheimer’s treatment targets toxic brain plaques called beta amyloid. AC Immune, a Swiss biotech company with a once-failed amyloid treatment of its own, rose about 26%. Prothena, which has an amyloid-targeting drug in early-stage development, went up 27%.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]